Get the Stockscreener App
8.91
1.33%
-0.12
After Hours:
8.91
Aura Biosciences Inc stock is traded at $8.91, with a volume of 148.84K.
It is down -1.33% in the last 24 hours and up +12.08% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$9.03
Open:
$8.86
24h Volume:
148.84K
Relative Volume:
0.81
Market Cap:
$446.95M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-4.455
EPS:
-2
Net Cash Flow:
$-64.56M
1W Performance:
-1.98%
1M Performance:
+12.08%
6M Performance:
+13.50%
1Y Performance:
-0.67%
1-Day Range:
$8.84
$9.41
1-Week Range:
$8.62
$9.47
52-Week Range:
$5.99
$12.35
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Where are the Opportunities in (AURA) - Stock Traders Daily
Ensign Peak Advisors Inc Sells 105,316 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences names interim CFO as Julie Feder departs By Investing.com - Investing.com Australia
Aura Biosciences names interim CFO as Julie Feder departs - Investing.com
Wall Street SWOT: Aura Biosciences stock shows promise amid cancer treatment trials - Investing.com
Aura Biosciences Executives Transition and Compensation Update - TipRanks
Long Focus Capital Management LLC Has $7.99 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Energy (LON:AURA) Trading 11.1% Higher - MarketBeat
Bioxyne signs amendment with Aura Therapeutics to manufacture product volumes - Biotech Dispatch
Aurora Films to Go Public in Q4 2024 With Exclusive Token Issuance - EIN News
A Guide To The Risks Of Investing In Aurora Innovation Inc (AUR) - Knox Daily
Hancock Whitney Corp Makes New Investment in Acuity Brands, Inc. (NYSE:AYI) - Defense World
Financial Health Check: Examining Aurora Innovation Inc (AUR)’s Key Ratios - The Dwinnex
Should investors be concerned about Aurora Innovation Inc (AUR)? - US Post News
Bank of New York Mellon Corp Acquires 48,549 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + - Seeking Alpha
Aurora Innovation (NASDAQ:AUR) Hits New 52-Week High at $5.31 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Stock Rating Upgraded by Evercore ISI - MarketBeat
Aura Biosciences (NASDAQ:AURA) Raised to Strong-Buy at Evercore ISI - Defense World
$200M Cash, 8.8% Dividend Yield w/ 450K oz Gold Target | Aura Minerals with Rodrigo Barbosa - The Deep Dive
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 5.7% in August - Defense World
aura Launches a One-Hour At-Home Health Check, Going Far Beyond Standard Blood Work - Business Wire
NCR's Realty Giant Gaurs Group Plans IPO, CMD Reveals Timeline, Projects and Other Details - News18
Aura Biosciences: Highly Derisked Late Stage Eye Cancer Company (NASDAQ:AURA) - Seeking Alpha
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at JMP Securities - MarketBeat
Aura Biosciences' (AURA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Zacks Investment Research
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Yahoo Finance
Aura Biosciences (NASDAQ:AURA) Shares Gap Up to $9.07 - MarketBeat
Aura Biosciences Touts Promising Data From Eye Cancer Candidate - Benzinga
Aura Biosciences Shares Jump in Premarket on Positive Phase 2 Ocular Cancer Treatment Results - MarketWatch
Lifesci Capital Comments on Aura Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:AURA) - MarketBeat
Aura reports promising results for ocular cancer therapy - Investing.com
Aura Biosciences’ Breakthrough in Choroidal Melanoma Treatment - TipRanks
Positive Phase II Bolsters Aura Bioscience’s Confidence in VDC-based Therapy for Ocular Melanomas - Genetic Engineering & Biotechnology News
Aura Biosciences Reports Positive Phase 2 End of Study - GlobeNewswire
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - StockTitan
Aura Biosciences (NASDAQ:AURA) Lifted to Strong-Buy at Lifesci Capital - Defense World
Lifesci Capital Upgrades Aura Biosciences (NASDAQ:AURA) to Strong-Buy - MarketBeat
We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely - Simply Wall St
Levin Capital Strategies L.P. Purchases 216,266 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate - Yahoo Finance
Aura Biosciences to Host a Urologic Oncology Investor Event - GlobeNewswire
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 - StockTitan
A look into Aura Biosciences Inc (AURA)’s deeper side - SETE News
(AURA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) Receives Market Outperform Rating from JMP Securities - Defense World
Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Aura Biosciences to Participate in Upcoming Investor Conferences - Marketscreener.com
Aura Biosciences to Participate in Upcoming Investor Conferences - StockTitan
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):